Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia
In the isolated perfused pancreas, gastric inhibitory polypeptide (GIP) has been shown to enhance glucagon secretion at basal glucose concentrations, but in healthy humans no glucagonotropic effect of GIP has yet been reported. Therefore, we studied the effect of GIP on glucagon secretion under normoglycaemic conditions.
Ten healthy subjects (9 men, 1 woman; age 33±11; BMI 26.8±2.2 kg/m2) received three different doses of intravenous GIP (7, 20, and 60 pmol/kg body weight) and placebo. Venous blood samples were drawn over 30 min for glucagon and GIP concentrations (specific radioimmunoassays). In addition, 31 healthy subjects (16 men, 15 women; 42±11 years; BMI 24.4±2.7 kg/m2) were studied with 20 pmol GIP/kg. Statistics were done with RM-ANOVA and Duncan's post hoc tests.
Gastric inhibitory polypeptide dose-dependently stimulated glucagon secretion (p=0.019) with a maximal increment after 10 min. Incremental glucagon concentrations (Δ10–0 min) were 0.1±0.7, 1.4±0.5, 2.4±0.5, and 3.4±0.8 pmol/l (for placebo and for 7, 20, and 60 pmol GIP/kg, respectively; p=0.017). After the injection of 20 pmol GIP/kg b.w. in 31 healthy subjects, glucagon concentrations increased over the baseline from 7.5±0.5 to 9.3±0.7 pmol/l (p=0.0082).
Glucagon secretion is dose-dependently stimulated by GIP at basal glucose concentrations. The absence of a glucagonotropic GIP effect in previous studies could be due to the hyperglycaemic conditions used in these experiments. Our results underline differences between GIP and the glucagonostatic incretin GLP-1.
- Creutzfeldt W, Nauck M (1992) Gut hormones and diabetes mellitus. Diabetes Metab Rev 8:149–177
- Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301–307
- Meier JJ, Hücking K, Holst JJ, Deacon C, Schmiegel W, Nauck MA (2001) Reduced insulinotropic effect of Gastric Inhibitory Polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50:2497–2504
- Pederson RA, Brown JC (1978) Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secreton from the perfused rat pancreas. Endocrinol 103:610–615
- Deacon CF, Nauck MA, Meier JJ, Hücking K, Holst JJ (2000) Degradation of endogenous and exogenous Gastric Inhibitory Polypeptide (GIP) in healthy and in Type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575–3581
- Holst JJ (1982) Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33–69) of glicentin. Biochem J 207:381–388
- Meier JJ, Nauck MA, Schmidt WE, Gallwitz B (2002) Gastric Inhibitory Polypeptide (GIP): The neglected incretin revisited. Regul Peptides 107:1–13
- Dupré J, Caissignac Y, McDonald TJ, Van Vliet S (1991) Stimulation of glucagon secretion by gastric inhibitory polypeptide in patients with hepatic cirrhosis and hyperglucagonemia. J Clin Endocrinol Metab 72:125–129
- Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609–613
- O'Harte FP, Gault VA, Parker JC, Harriott P, Mooney MH, Bailey CJ, et al. (2002) Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia 45:1281–1291
- Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia
Volume 46, Issue 6 , pp 798-801
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Gastric inhibitory polypeptide
- incretin hormones
- glucose homeostasis
- Industry Sectors
- Author Affiliations
- A1. Medizinische Klinik I, St. Josef-Hospital, Klinikum der Ruhr-Universität Bochum, Gudrunstraße 56, 44791, Bochum, Germany
- A2. Department of Medicine I, St. Josef-Hospital, Ruhr-University Bochum, Germany
- A3. Department of Medical Physiology, The Panum Institute, University of Copenhagen, Denmark
- A4. Diabeteszentrum Bad Lauterberg, Germany